Status:
RECRUITING
The Predictive Role of Proteomics in Blood Pressure Response of Hypertensive Patients Undergoing Renal Denervation.
Lead Sponsor:
Hippocration General Hospital
Collaborating Sponsors:
National and Kapodistrian University of Athens
Biomedical Research Foundation, Academy of Athens
Conditions:
Hypertension
Renal Denervation
Eligibility:
All Genders
18-80 years
Brief Summary
Renal sympathetic nervous activity plays a crucial role in the development and maintenance of hypertension (HTN). Renal denervation (RDN) is a minimally invasive catheter-based treatment using mainly ...
Detailed Description
Hypertension (HTN) is the most prevalent modifiable risk factor associated with cardiovascular morbidity and mortality, while its prevalence is rising globally. Despite the availability of safe and ef...
Eligibility Criteria
Inclusion
- All treated patients have to be on standard antihypertensive regimens for at least 8 weeks
- Age 18-80 years
- Office systolic blood pressure ≥140 mmHg and
- Ambulatory systolic blood pressure ≥130 mmHg
Exclusion
- eGFR \<45mL/min/1.73m2
- Renal artery abnormalities
- Type I diabetes mellitus
- Secondary hypertension
- Pregnant or breastfeeding women
- Psychiatric or neurological disease which does not allow adequate co-operation
- Active cancer on treatment
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06208501
Start Date
September 1 2023
End Date
September 1 2025
Last Update
February 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Cardiology Clinic, Hippokration General Hospital, National and Kapodistrian University of Athens
Athens, Greece